Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) protects and informs Canadian consumers by regulating the prices of patented medicines sold in Canada, and by reporting on pharmaceutical trends.

We are an independent quasi-judicial body that is part of the Health portfolio, and operate at arm’s-length from the Minister of Health.

Department name


We are in the process of moving our services and information to

Our current Patented Medicine Prices Review Board website will remain available until the move to is complete.

Latest news

New Notice and Comment

New Notice and Comment

The PMPRB invites stakeholders to comment on its proposed approach for conducting interim price reviews while the PMPRB consults its stakeholders on new guidelines.

Meds Pipeline Monitor 2021

Meds Pipeline Monitor 2021

This 11th edition features a selection of medicines in Phase III clinical trials or pre-registration in 2021 that have the potential to significantly impact clinical practice and drug spending in Canada.

What we are doing

Corporate information


Regulatory Process

The PMPRB is responsible for ensuring the prices that patentees charge for prescription and non-prescription patented medicines sold in Canada to wholesalers, hospitals, pharmacies or others, for human and veterinary use, are not excessive.

NPDUIS reporting

Every report and publication published by the NPDUIS group.



Effective and meaningful stakeholder involvement is essential to enable the PMPRB to fulfil its mandate, deliver programs, launch new initiatives, and build public trust.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: